Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.

MLA

Zhao, Xiangxuan, et al. “Focal Adhesion Kinase Inhibitor PF573228 and Death Receptor 5 Agonist Lexatumumab Synergistically Induce Apoptosis in Pancreatic Carcinoma.” Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine, vol. 39, no. 5, May 2017, p. 1010428317699120. EBSCOhost, https://doi.org/10.1177/1010428317699120.

APA

Zhao, X., Sun, W., Puszyk, W. M., Wallet, S., Hochwald, S., Robertson, K., & Liu, C. (2017). Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma. Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine, 39(5), 1010428317699120. https://doi.org/10.1177/1010428317699120

Chicago

Zhao, Xiangxuan, Wei Sun, William M Puszyk, Shannon Wallet, Steve Hochwald, Keith Robertson, and Chen Liu. 2017. “Focal Adhesion Kinase Inhibitor PF573228 and Death Receptor 5 Agonist Lexatumumab Synergistically Induce Apoptosis in Pancreatic Carcinoma.” Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine 39 (5): 1010428317699120. doi:10.1177/1010428317699120.